Evidence map›Paper›PMID 37815188›Full record

ReviewCurrent stem cell research & therapy2024

Clinical Trials of Mesenchymal Stem Cells for the Treatment of COVID 19.

Elham Zendedel, Lobat Tayebi, Mohammad Nikbakht, Elham Hasanzadeh, Shiva Asadpour

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current stem cell research & therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Elham ZendedelDepartment of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran.ORCID 0000-0001-8698-0326
Lobat TayebiMarquett University School of Dentistry, Milwaukee, WI, 53233, USA.ORCID 0000-0003-1947-5658
Mohammad NikbakhtDepartment of Medical Biotechnology, School of Advanced Technologies, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Elham HasanzadehImmunogenetics Research Center, Department of Tissue Engineering & Regenerative Medicine, School of Advanced Technologies in Medicine, Mazandaran University of Medical Sciences, Sari, Iran.ORCID 0000-0002-8286-6013
Shiva AsadpourDepartment of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran.ORCID 0000-0001-5574-7142

Funding

Supplement: Development of an Integrated 3D Human Osteo-Mucosal ModelR15DE027533 · NIDCR · MARQUETTE UNIVERSITY · PI TAYEBI, LOBAT · 2018 to 2021
$816k
NIH HHS R15DE027533Shahrekord University of Medical Sciences 3161
6 · The paper itself

Abstract

Mesenchymal Stem Cells (MSCs) are being investigated as a treatment for a novel viral disease owing to their immunomodulatory, anti-inflammatory, tissue repair and regeneration characteristics, however, the exact processes are unknown. MSC therapy was found to be effective in lowering immune system overactivation and increasing endogenous healing after SARS-CoV-2 infection by improving the pulmonary microenvironment. Many studies on mesenchymal stem cells have been undertaken concurrently, and we may help speed up the effectiveness of these studies by collecting and statistically analyzing data from them. Based on clinical trial information found on clinicaltrials. gov and on 16 November 2020, which includes 63 clinical trials in the field of patient treatment with COVID-19 using MSCs, according to the trend of increasing studies in this field, and with the help of meta-analysis studies, it is possible to hope that the promise of MSCs will one day be realized. The potential therapeutic applications of MSCs for COVID-19 are investigated in this study.

Indexed as

Clinical Trials as TopicCOVID-19Mesenchymal Stem CellsMesenchymal Stem Cell TransplantationSARS-CoV-2Humanscell therapyclinical trialsCovid-19mesenchymal stem cell (MSCs)regenerative medicineSARS-CoV-2.

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.